SCHEMBL6761129

SCHEMBL6761129

CS(=O)(=O)OCCCCCNC(=O)CCc1ccccc1Sc1ccc(Cl)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.41
ALDH1A1 P00352 4/20 0.41
BLM P54132 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
NOD2 Q9HC29 1/20 0.41
MC4R P32245 1/20 0.40
HTT P42858 2/20 0.40
POLB P06746 2/20 0.40
HSD17B10 Q99714 1/20 0.40
MMP2 P08253 1/20 0.39
MMP9 P14780 1/20 0.39
MMP12 P39900 1/20 0.39
SLC6A4 P31645 1/20 0.39
TSHR P16473 1/20 0.38
KDM4E B2RXH2 1/20 0.37
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
CHRM2 P08172 2/20 0.36
BCHE P06276 1/20 0.36
ACHE P22303 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6763050 0.99 LMNA (0.42) LMNAALDH1A1BLMNPSR1NOD2
SCHEMBL6759484 0.86 LMNA (0.44) LMNAALDH1A1BLMNPSR1NOD2
SCHEMBL6761155 0.85 LMNA (0.46) LMNAALDH1A1BLMNPSR1NOD2
SCHEMBL6762867 0.84 LMNA (0.46) LMNAALDH1A1BLMNPSR1NOD2
SCHEMBL6763799 0.84 LMNA (0.47) LMNAALDH1A1BLMNPSR1NOD2
SCHEMBL6761995 0.84 LMNA (0.47) LMNAALDH1A1BLMNPSR1NOD2
SCHEMBL6762149 0.82 LMNA (0.48) LMNAALDH1A1BLMNPSR1NOD2
SCHEMBL5019657 0.81 SLC6A4 (0.51) LMNAALDH1A1BLMNPSR1NOD2
SCHEMBL6766233 0.79 LMNA (0.45) LMNAALDH1A1BLMNPSR1NOD2
SCHEMBL23666455 0.77 SLC6A4 (0.54) LMNAALDH1A1BLMNPSR1NOD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040192680-A1 Novel amides that activate soluble guanylate cyclase ABBOTT LABORATORIES 2004-09-30 US disclosed
US-20040121994-A1 Novel amides that activate soluble guanylate cyclase ABBOTT LABORATORIES 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040121994-A1 Novel amides that activate soluble guanylate cyclase GUCY1A1, GUCY1B1, GUCY1A2 LMNA 2027/4885ALDH1A1 510/4885BLM 3751/4885
US-20040192680-A1 Novel amides that activate soluble guanylate cyclase GUCY1A1, GUCY1B1, GUCY1A2 LMNA 2027/4885ALDH1A1 510/4885BLM 3751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.